Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Executive Summary
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.